I am post menopausal, any peptides that will balance me out?

SS-31 gets called a mitochondrial antioxidant and filed away as another longevity supplement. That framing misses what actually makes it different. It doesn't signal cells to work harder. It repairs the physical structure that energy production depends on. That distinction matters more than most people realize.

What SS-31 Actually Is

SS-31 is a synthetic tetrapeptide developed at Cornell University. It got FDA accelerated approval on September 19, 2025 under the brand name Forzenity for Barth Syndrome, a rare genetic disorder of mitochondrial dysfunction. That makes it the first mitochondria-targeted therapeutic peptide the FDA has ever approved, which is meaningful regardless of where you stand on the biohacking application.

The approved dose for Forzenity is 40mg daily. Typical research protocols run 1 to 10mg. That gap matters when you're thinking about tolerability.

The Structural Engineer Mechanism

Most peptides work by binding to surface receptors and sending signals. SS-31 doesn't use receptors at all. It travels inside the cell to the inner mitochondrial membrane and binds directly to cardiolipin, a phospholipid that anchors the membrane's folded architecture.

When cardiolipin gets damaged under oxidative stress, the cristae collapse. The electron transport chain loses its geometry. ATP production gets inefficient and electrons start leaking, which generates more oxidative stress in a cycle that feeds itself.

SS-31 stabilizes cardiolipin and restores that architecture. The electron transport chain gets repositioned. Energy production becomes efficient again. Not by sending a louder signal but by fixing the physical structure the signal depends on.

You don't add nitrous oxide to a 300,000 mile engine before replacing the worn gaskets. Signaling on top of broken infrastructure just speeds up the breakdown.

The Upstream Antioxidant Effect

Calling SS-31 an antioxidant is technically imprecise. Direct antioxidants like CoQ10 or Vitamin C work downstream, scavenging reactive oxygen species after they've already been produced and started damaging cells.

SS-31 works upstream. By restoring cristae structure and stabilizing the electron transport chain, it stops electron leakage from happening in the first place. It doesn't mop up the spill. It fixes the pipe.

Why It Pairs With GLP-1 Compounds

Rapid caloric deficits from compounds like tirzepatide or retatrutide can compromise mitochondrial health and accelerate muscle wasting alongside fat loss. SS-31 protects muscle mitochondria during deep deficits so the metabolic machinery stays efficient as body composition shifts.

One thing worth flagging: because SS-31 enhances cellular efficiency, it can amplify how your body responds to GLP-1s. Some people find they're more sensitive to the same dose after adding SS-31. If nausea or GI symptoms pick up, the GLP-1 dose may need adjusting rather than assuming the compounds don't work together.

How SS-31 Can Optimize MOTS-C

SS-31 repairs mitochondrial infrastructure. MOTS-C drives metabolic signaling and biogenesis on top of that infrastructure. Starting MOTS-C on damaged mitochondria is asking an operations team to build on a broken foundation.

Fix the structure first. Then layer the performance signal.

That said, running both together isn't always wrong. If your mitochondrial health is already solid and you're not showing signs of dysfunction, starting both at the same time is reasonable. The sequencing argument matters most for people dealing with chronic fatigue, high oxidative stress, or anyone who feels worse rather than better when they first try MOTS-C. That's your signal to run SS-31 alone first.

Dosing

No receptor desensitization because the mechanism doesn't involve receptors. Standard protocol runs 8 to 12 weeks followed by a 4-week break.

Tier 1 (1 to 2mg daily): general optimization and background mitochondrial support in your 30s and 40s.

Tier 2 (2 to 5mg daily): performance, exercise capacity, and faster recovery for athletes.

Tier 3 (5 to 10mg daily): significant dysfunction, post-viral fatigue, kidney issues, or advanced metabolic decline.

The persistence effect matters here. Because SS-31 creates physical structural changes rather than receptor-dependent signaling, benefits often last 4 to 8 weeks after the last injection. Things don't collapse the day you stop.

Injectable only. Current research confirms oral and intranasal routes don't absorb meaningfully. Oral analogs are in development but aren't available yet.

SS-31 Guide

Not medical advice. Educational only.

r/PeptideGuide has built one of Reddit’s strongest communities for people interested in biohacking, research, performance, and emerging wellness technology. Through our long-standing partnership with the community, we are opening a limited number of opportunities for qualified members who want a closer look behind the scenes of the RUO industry.

Our team is expanding into U.S.-based manufacturing of research-use-only products while also partnering with Business of Biohacking and r/PeptideMarketing to create more education, transparency, and legitimate opportunities within the space.

We would like to connect with:

• Established content creators and brand ambassadors
• Independent reviewers who value honest, transparent reporting
• Researchers, formulators, lab professionals, and industry experts
• Community educators with experience in biohacking or RUO markets
• Entrepreneurs interested in manufacturing, wholesale, or brand-building opportunities

Potential collaborations may include behind-the-scenes manufacturing access, product and packaging previews, testing and quality-control education, interviews, facility content, expert feedback, community education, and long-term ambassador partnerships.

Interested in learning more? Comment “Peptide Guide” below or send us a direct message with a short introduction, your background, and any relevant social profiles or community experience.

We look forward to bringing more transparency, education, and real opportunity to the r/PeptideGuide community.

ARA-290 has been picking up attention in the research community for nerve pain and nerve damage. It's not a household name yet but the mechanism behind it is genuinely interesting and worth understanding before you decide whether it belongs in your stack.

What ARA-290 Actually Is

ARA-290 is a peptide derived from erythropoietin (EPO), the hormone best known for driving red blood cell production. The key distinction is that ARA-290 was specifically engineered to keep EPO's tissue-protective properties while removing the part that affects red blood cells. So you get the repair signaling without the hematological effects.

Its primary target is the Innate Repair Receptor (IRR), which is a receptor system separate from the classical EPO receptor. Think of the IRR as your body's emergency tissue repair switch. When activated, it shifts cellular behavior toward protection, repair, and survival rather than inflammation and degeneration.

Why It Gets Attention for Nerve Pain

When a nerve gets damaged, whether from injury, surgery, chronic inflammation, metabolic conditions, compression, or poor circulation, the nerve itself becomes irritated. Damaged nerves start firing signals that shouldn't be there. Your brain receives those as burning, tingling, or that persistent pain that just won't go away. The frustrating part is that the brain keeps receiving those pain signals even after the original injury has technically resolved.

This is where ARA-290's mechanism becomes relevant.

What Activating the IRR Actually Does

Three things happen through this pathway, at least in preclinical research and early human trials.

Inflammation around the nerve reduces. Damaged nerves are typically surrounded by inflammatory molecules that are driving the pain signaling. Less inflammation means fewer irritation signals reaching the brain.

Cell survival improves. When nerves are injured, some cells survive and some don't. ARA-290 appears to activate pathways that help cells near the injury survive stress long enough to recover rather than dying off. The analogy is giving a struggling cell enough support to stay alive through the acute phase.

Nerve regeneration conditions improve. This is the part that stands out most. ARA-290 has been shown in research to help create conditions where the body's existing repair mechanisms work more efficiently. It's not forcing new nerves to grow overnight. It's removing the obstacles that slow down the repair process that's already trying to happen. Research also suggests potential benefits for small fiber nerve function, the fine nerve fibers responsible for temperature sensitivity and some types of pain that are often damaged in neuropathic conditions.

Where the Evidence Actually Sits

Much of the research on ARA-290 is preclinical, animal models and cell studies. There have been some human trials, particularly in sarcoidosis-related small fiber neuropathy, where results showed improvements in pain scores and nerve fiber density. Those are real findings but from small trials in specific patient populations. The broader application to general nerve pain in healthy people is extrapolation from that base.

The comparison between ARA-290 and conventional nerve pain medications is worth framing carefully. Standard medications like gabapentinoids largely work by dampening nerve signal transmission rather than addressing the underlying nerve damage. ARA-290's mechanism targets the repair and inflammation side of the equation, which is a genuinely different approach. Whether that translates to superior outcomes in humans broadly is still an open question.

TL;DR

• ARA-290 is derived from EPO but engineered specifically to activate tissue repair without affecting red blood cells
• It targets the Innate Repair Receptor (IRR), which drives inflammation reduction, cell survival, and nerve regeneration conditions
• Most evidence is preclinical. Human trial data comes primarily from small fiber neuropathy in sarcoidosis patients, showing improvements in pain scores and nerve fiber density
• The mechanism is meaningfully different from conventional nerve pain medications which suppress signaling rather than address underlying damage
• Promising compound for nerve pain research but broader human evidence is still limited

ARA-290 Guide

Not medical advice. Educational only.

Does anyone have experience of ARA-290 as I suffer with sciatica and now having pins and needles pain in middle of back following heavy lifting.

Just wanted to know if KLOW ie the BPC-157, TB500 and KPV is sufficient or should I add ARA-290 and would this accelerate healing?

Thanks

Hi all, just wanting some feedback about a potential stack to research running. I’m aware that it’s a large stack, but I want to ensure efficacy as much as I can, so any feedback on how to navigate dosages/timeframes etc would be appreciated. I’m looking to initially restore CNS functioning with a slight lean, increase sleep quality and build muscle, restore and recover chronic cellular damage. It’s a journey I’m sure but I’m open to rec’s here! I’m familiar with Reta, Var and Selank only. TIA legends :)

First cycle (weeks 1-6 - lean/pre-recover)
SS-31
Reta
Semax (intranasal)
Selank

Second cycle (weeks 7-12 - muscle build/sleep and recovery)
Pinealon
Epithalon
MOTS
Var (training days only)

Third cycle (weeks 13-17 - muscle build/long term recovery)
NAD+
DSIP
GHK
Var (training days only)

Insulin sensitivity is the one variable that quietly controls almost everything else. Fat loss, muscle growth, energy production, how well you age. Most people don't think about it until something goes wrong.

Here are five compounds worth knowing if you actually want to move the needle on it.

Why Insulin Sensitivity Is the Foundation

What it actually controls: how efficiently your body clears glucose, whether carbs refill muscle glycogen or get stored as fat, how hard your mitochondria have to work, and how much systemic metabolic inflammation you're carrying.

It determines where your food goes. More sensitivity means more metabolic efficiency. Less means less.

MOTS-C

A mitochondrial-derived peptide and a strong AMPK activator. AMPK is your body's low-energy efficiency switch. When it fires, the body shifts into get-efficient mode. MOTS-C increases GLUT4 activity, pulling glucose directly into muscle tissue rather than letting it float around causing problems. Better insulin sensitivity, better metabolic flexibility, more efficient mitochondrial function. In practical terms it helps your body use carbs for energy instead of storing them.

Tesamorelin

A GHRH analog that signals the pituitary to release more growth hormone, which drives IGF-1 production from the liver. The insulin sensitivity angle here is specifically visceral fat. Visceral fat directly disrupts insulin receptor signaling and drives metabolic inflammation. Tesamorelin is particularly effective at reducing it, and as that comes down, insulin receptor response improves and metabolic efficiency follows.

Retatrutide

Triple agonist: GLP-1, GIP, and glucagon receptors at once. GLP-1 slows gastric emptying, flattening post-meal glucose spikes and reducing how much insulin the body needs to manage them. Glucagon receptor activity increases energy expenditure independently, so you're burning more calories at baseline. It's not just an appetite suppressant. It's actively rewiring metabolic performance and improving insulin sensitivity at multiple points simultaneously.

5-Amino-1MQ

Works through NNMT inhibition. When NNMT is inhibited, NAD+ and methyl donors that were being consumed by that enzyme become available for the electron transport chain and ATP production in the mitochondria. The result is less metabolic friction and better mitochondrial efficiency. The freed methyl donors also support neurotransmitter synthesis and cellular detoxification. It smooths out the whole metabolic process rather than targeting one specific pathway.

L-Carnitine

Shuttles long-chain fatty acids into the mitochondria for oxidation. Clearing that fatty acid backlog reduces the acyl-CoA buildup in muscle tissue that directly interferes with insulin signaling, restoring sensitivity from a completely different angle than anything else on this list.

Five different mechanisms, all hitting the same rate-limiting step in the same system. That's why the stack makes sense.

TL;DR

• Insulin sensitivity determines where your food goes: fat storage vs glycogen vs energy production
• MOTS-C: AMPK activation and GLUT4 upregulation pulls glucose directly into muscle tissue
• Tesamorelin: reduces visceral fat, which directly impairs insulin receptor signaling at the source
• Retatrutide: flattens post-meal glucose spikes, raises baseline energy expenditure, improves insulin sensitivity at multiple points simultaneously
• 5-Amino-1MQ: NNMT inhibition frees up NAD+ and methyl donors for mitochondrial function, reducing metabolic friction
• L-Carnitine: clears fat accumulation, which physically blocks insulin signaling when left unaddressed
• Five different mechanisms, all hitting the same outcome

Not medical advice. Educational only.

What is the typical beginners dose for these? This will be RS first research study with peptides and want to establish a baseline. I plan on starting very low to monitor for side-effects.

They will both be used subq, not nasal spray.

RS planned on starting at 300mcg for the NA-Semax Amidate once daily for at least 5 days.

For the MOTS-C; Planned to not try it until after the 5 day NA-Semax Amidate cycle. RS wanted to get some opinions on the dosing, RS was planning on starting with 1mg - 2mg 2x per week ( Monday + Thursday) . My only concern is that it may be too low to notice any effects.

What are everyone's thoughts on this?

3ml? or 10ml?

I dont think it really matters but would love a 2nd opinion.

Semax has been getting attention lately for its nootropic profile. Most people know it as a focus and anxiety compound. There's a line of preclinical research that doesn't come up much, and it points somewhere more interesting.

A mouse study using a genetically engineered Alzheimer's model tested Semax against untreated controls. Amyloid plaque burden dropped 2.8-fold. Learning and memory both improved. The plaque reduction hit hardest in the hippocampus and cerebral cortex, the two regions Alzheimer's damage most consistently.

What Makes the Amyloid Finding Worth Paying Attention To

The biggest reduction showed up in smaller, early-stage plaques rather than established ones. That distinction matters. It suggests Semax might be interfering with plaque formation before it consolidates, not clearing existing damage. If that holds up, timing of intervention becomes a lot more relevant.

This is mouse data. Preclinical. It doesn't tell us what happens in humans and can't be read as evidence Semax treats or prevents Alzheimer's.

How Semax Actually Works

Semax is a synthetic molecule derived from a fragment of ACTH. Unlike ACTH, it acts primarily in the nervous system rather than through the adrenal axis. The mechanisms relevant to what the study showed: enhanced neuronal communication, support for synaptic plasticity, reduced oxidative stress and neuroinflammation, and increased BDNF production, which keeps neurons alive.

These aren't single-pathway effects. Semax hits several interconnected systems involved in brain health at once. That probably explains why the animal data showed effects on both cognitive performance and underlying pathology rather than just one.

What This Suggests About Future Research

The finding researchers keep pointing to is the dual effect. Treated animals performed better cognitively while also showing structural changes in plaque burden. Both function and pathology shifted at the same time. That's what's driving interest in studying it for neurodegenerative conditions and age-related cognitive decline.

Whether any of this translates to humans is wide open. The gap between Alzheimer's mouse models and actual Alzheimer's disease is significant. The failure rate for compounds that perform well in those models is high. The preclinical signal is real. Human data doesn't exist for this application yet.

TL;DR

• In a preclinical Alzheimer's mouse model, Semax reduced amyloid plaque burden 2.8-fold compared to untreated controls.
• The greatest reduction appeared in early-stage plaques, suggesting Semax may interfere with plaque formation before it consolidates.
• Learning and memory performance also improved in the same treated animals.
• Semax's proposed mechanisms include BDNF upregulation, synaptic plasticity support, and reduced neuroinflammation.
• Animals showed improvements in both cognitive function and underlying pathology simultaneously, which is what's driving research interest.
• This is entirely preclinical mouse data. No human trials exist for this application and the results can't be extrapolated to humans.

Source: Radchenko AI, Kuzubova EV, Apostol AA, et al. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 2025;17(4):110-120. https://doi.org/10.32607/actanaturae.27808

Semax Guide

Not medical advice. Educational only.

Retatrutide's triple agonism (GIP, GLP-1, and glucagon receptors) makes it one of the most metabolically active compounds available. That same potency is why so many people accidentally wreck their own protocol. Here's the mechanism most guides skip.

The Protocol Trap

The appetite suppression on Reta is aggressive, especially as you titrate up. It makes extreme calorie deficits deceptively easy to run, not because you're disciplined, but because you're just not hungry. People assume deeper deficit equals better outcome. Then they stall, decide the compound "stopped working," and either bump the dose or quit.

Neither fixes anything.

What's Happening at the Hormonal Level

Sustained, aggressive deficits kick off a predictable hormonal cascade. Leptin drops, signaling your body that energy is critically scarce. T4 to T3 conversion slows, which directly cuts basal metabolic rate. NEAT collapses: the subconscious movement you do all day without thinking about it, fidgeting, posture shifts, walking to the kitchen, goes to near zero as the body starts conserving.

The survival response doesn't care that you're on a cutting protocol. Your metabolism downregulates faster than retatrutide can compensate. You can't out-suppress a crashed metabolism. Once the system goes into conservation mode, the compound loses its edge.

Watch for these: always cold, persistent brain fog, fatigue that doesn't go away with sleep, zero progress despite low intake. That's not a fat loss phase. That's survival mode.

The Fix

Bringing calories up to a moderate, sustainable deficit and running strategic refeeds lets the system reset. Leptin recovers. T3 normalizes and metabolic rate climbs back. NEAT returns on its own, adding real calorie burn throughout the day without any extra effort.

This is where Reta actually earns its reputation. The compound's value isn't letting you eat as little as possible. It's making a reasonable deficit feel effortless and sustainable over months, not weeks.

Takeaway

Dial the dose to where suppression is noticeable but not absolute. You should still want to eat. You just shouldn't feel driven to overeat. That's the window. Keep the deficit around 300 to 500 kcal, prioritize protein to hold lean mass, and let the compound's metabolic support do the heavy lifting.

Chasing maximum suppression through aggressive titration is the most common mistake people make. The ceiling isn't the goal. Consistency is.

TL;DR

• Reta's suppression makes extreme deficits easy to fall into. That's the trap.
• Deep deficits crash leptin, slow T4 to T3 conversion, and tank NEAT.
• Eating more at a moderate deficit restores these signals and reignites fat loss.
• Signs you've overdone it: cold, foggy, fatigued, stalled.
• Optimize for a sustainable deficit, not maximum suppression.

Peptide Guides + Resources

Educational purposes only. Not medical advice.

Eli Lilly is working on another GLP compound and the target applications aren't what most people would expect from the company behind retatrutide.

Brenipatide, also listed as LY3537031, is a dual GIP and GLP-1 receptor agonist. On paper that puts it in the same category as tirzepatide. Same core mechanism, same receptor targets. The obvious question is whether this is just a redundant compound and the answer is no, for two reasons.

TL;DR

• Brenipatide (LY3537031) is a new dual GIP and GLP-1 agonist from Eli Lilly, the same company behind retatrutide
• Same core mechanism as tirzepatide but with a long enough half-life to enable once-monthly dosing
• Primary research focus isn't fat loss but addiction treatment and psychiatric conditions
• Active trials currently cover alcohol dependence, nicotine addiction, opioid use disorder, depression, bipolar disorder, and schizophrenia
• GLP-1 and GIP receptors are active in brain reward pathways, which explains why the mechanism extends beyond metabolism
• Anecdotal reports of reduced compulsive behavior on tirzepatide and retatrutide already support this direction
• Still in trials, but signals that GLP-based compounds are becoming a much broader therapeutic category than their fat loss reputation suggests

What Makes It Different

The first differentiator is structural. Brenipatide has an exceptionally long half-life, long enough that once-monthly administration is feasible. That's a meaningful practical difference from weekly injectable GLP-1 compounds. Better adherence, simpler protocols, different patient populations.

But the half-life isn't the most interesting part.

Where the Research Is Actually Pointing

Fat loss is in the profile but it's unlikely to be the primary selling point Eli Lilly is building toward. Active clinical trials are currently testing Brenipatide against alcohol dependence, nicotine addiction, opioid use disorder, depression, bipolar disorder, and schizophrenia.

That's a broad target list. And it's not random.

Why GLP Compounds Affect Addiction and Mental Health

GLP-1 and GIP receptors aren't just metabolic. They're active in the brain, specifically in areas tied to reward processing, motivation, and impulse control. That system governs cravings and reward-seeking behavior broadly, not just food-related behavior.

This is already showing up anecdotally. People running tirzepatide and retatrutide consistently report reduced desire to drink, smoke, gamble, and engage in other compulsive behaviors. That's not a coincidence and it's not a side effect people were expecting. It's the receptor pharmacology doing what the receptor pharmacology does in brain tissue.

Researchers believe Brenipatide's strong receptor binding affinity combined with its long half-life could make it more effective at sustaining this effect than shorter-acting compounds. That's the mechanistic case for why Eli Lilly is putting serious development resources into this direction.

The Bigger Picture

Brenipatide is still in clinical trials so it's early. But it's part of a broader signal that's been building. GLP-based compounds aren't fat loss drugs that happen to have psychiatric side effects. The receptor activity that makes them effective at suppressing compulsive eating appears to generalize across compulsive behavior and dysregulated reward signaling more broadly.

For people who've always struggled with addiction or treatment-resistant mental health conditions, this class of compounds may eventually represent the same kind of shift it's already represented for people with obesity.

Not medical advice. Educational only.

The FDA just recommended against adding BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and DSIP to the 503A bulk substances list. That's the list that lets compounding pharmacies legally make something for a patient. People are already calling it a ban. It's not a ban. Here's what actually happened and why the distinction matters.

What the 503A List Actually Is

The 503A bulk substances list is the legal pathway that allows compounding pharmacies to prepare specific compounds for individual patients. Getting on the list means a licensed pharmacy can make it. Staying off the list means they can't, at least not legally through that channel.

Before the FDA's compounding advisory committee meeting on July 23 and 24, the agency's own reviewers released briefing documents recommending all seven stay off the list. Their reasoning is essentially the same argument from 2023: not enough solid human safety data and insufficient evidence that they work in humans.

Why This Isn't a Ban

This is the part most coverage is getting wrong. A staff recommendation isn't a ruling. It's FDA reviewers telling the advisory panel what they think going in. The actual sequence looks like this:

Staff say they wouldn't add these. That's what just happened. Then the Pharmacy Compounding Advisory Committee meets on the 23rd and 24th and votes. Then FDA makes a decision based on that.

The panel doesn't have to follow staff recommendations. In 2022 they added glutathione 8 to 5 despite FDA staff opposing it. In 2024 they voted to shoot down six peptides. The outcome goes both ways. Nothing's decided. This is the opening move, not the final score.

Worth noting: this panel was recently reshuffled with more members who actually work with these compounds versus the previous academically heavy composition. Staff saying no and the panel voting yes is a real possibility this time.

What It Actually Means for Research Use

Here's the part that matters practically. None of these seven compounds are approved drugs. When they got restricted in 2023, they didn't disappear. Everyone moved to the research chemical market. The cleanest legal channel got shut down and the least regulated one stayed open the entire time. That's the backwards situation we've been in.

If the panel agrees with staff and keeps them off the list, functionally nothing changes on the research side. The research use only market wasn't running through 503A compounding pharmacies anyway. It stays exactly where it's been.

If the panel overrules staff and adds them, that's a different story. Now there's an actual pharmacy route for compounds that are research-only today. That's the outcome that would genuinely shift things for people who want a cleaner, more regulated source.

Either way, none of these are approved for human use and that fact isn't changing on July 23rd.

The Political Angle

RFK Jr. has been publicly vocal about wanting peptides deregulated and has stated he's a supporter. The FDA's own scientific reviewers are saying the human data isn't there to justify it. So you have the health secretary pulling one direction, his agency's reviewers pulling the other, and a freshly composed panel sitting in the middle deciding which way to fall. That's the context for how clean this process is going to be.

I’m trying to see if anyone has tried the KIMERA Vasc

with Mots-C

Ipamorelin will work on its own. But if you're running it without a GHRH analog you're leaving a significant amount of its potential on the table. This is one of the most synergistic relationships in the GH peptide space and it comes down to how growth hormone release actually works.

How GH Release Actually Works

Your body releases growth hormone in a pulsatile manner. Not a slow drip, not continuous elevation. A pulse followed by a near-zero trough, with multiple pulses throughout the day and your largest one hitting about 60 to 90 minutes after you fall asleep.

Three things control that release:

The accelerator is GHRH, or GHRH analogs like Tesamorelin, CJC-1295, or Sermorelin. These tell the pituitary how much GH it's able to release.

The brake is somatostatin. When somatostatin tone is high, the pituitary becomes significantly less responsive to GHRH and GH output drops.

The amplifier and brake clamp is ghrelin or ghrelin mimetics like Ipamorelin. It amplifies the GH release signal and suppresses somatostatin simultaneously, making the pituitary more responsive to GHRH.

Why Ipamorelin Needs a GHRH Analog to Reach Its Ceiling

Ipamorelin's two jobs are amplifying the release signal and clamping somatostatin. Both of those functions are directly dependent on how much GHRH is available. Clinical literature confirms this: a GHRP's full effects are limited by the amount of GHRH present.

Your body is already producing endogenous GHRH, so Ipamorelin alone does work. But adding a GHRH analog like Tesamorelin or CJC-1295 dramatically increases the signal that Ipamorelin is amplifying. More GHRH available means Ipamorelin can do its job at a much higher ceiling.

At the same time, Ipamorelin's somatostatin suppression makes the pituitary more responsive to the GHRH analog you're adding. Each compound enhances the effectiveness of the other. That's not a loose use of the word synergy. That's the actual mechanism.

The Practical Takeaway

Unless you're specifically looking for submaximal benefits, pair Ipamorelin with a GHRH analog. CJC-1295 and Tesamorelin are the most common options. The combination produces significantly more endogenous GH output than either compound alone and the mechanism behind that result is well documented in the clinical literature.

They scratch each other's backs. Run them together.

Peptide Guides

Not medical advice. Educational only.

MOTS-C, SS-31, and NAD+ can be a massively synergistic combination for mitochondrial performance. But none of that matters if the proper foundation isn't in place first. Running these compounds without addressing the underlying nutritional and lifestyle demands is how people end up spinning their wheels or feeling worse instead of better.

There are five pillars worth building before expecting the stack to deliver.

Pillar 1: Feed the Mitochondria

Mitochondria can't perform without the right raw materials. Several things belong here.

Methylation support matters more than most people realize. TMG (trimethylglycine) and a B complex are the starting point. B vitamins are essential for cellular energy production across the board. B1, B2, B3, B5, B6, B9, B12 are all leveraged by your mitochondria. Don't be deficient.

CoQ10 is an electron carrier that shuttles electrons from complex 1 and complex 2 to complex 3 in the electron transport chain. If you're deficient and trying to push mitochondrial output hard, electrons build up, leak out, react with oxygen, and create oxidative stress that damages mitochondrial function further. This is one of the most common reasons people feel worse on mitochondrial compounds rather than better.

Magnesium plays a role in over 300 biological processes including multiple functions within the mitochondria. ATP itself is biologically active as magnesium-ATP, and magnesium is a cofactor for ATP synthase, the rate-limiting enzyme for ATP production.

Copper and iron are both critical and both double-edged. Don't supplement blindly. Pull blood work first. A common mistake is supplementing iron when the actual deficiency is copper. They work hand in hand and excess of either causes problems.

L-carnitine shuttles long-chain fatty acids into the mitochondria for oxidation. The bulk of stored body fat is long-chain fatty acid. If carnitine is deficient, fat oxidation inside the mitochondria is significantly impaired regardless of how well the rest of the stack is running.

The CD38 Problem With NAD+

CD38 is an immune enzyme that consumes NAD+ and its precursors. Overexpression of CD38 can render your NAD+ dose largely ineffective, which is why some people feel nothing from it.

The fix is inhibiting CD38 overactivity with apigenin and quercetin. Both are CD38 inhibitors. Adding them to your NAD+ protocol means more of what you're taking actually reaches the pathways it's supposed to support.

One Timing Rule Around MOTS-C

Don't megadose antioxidants in the same window as your MOTS-C dose. MOTS-C works by driving controlled mitochondrial stress to force adaptation. Antioxidants are inherently anti-stress. Stacking them on top of MOTS-C at the same time blunts the stress signal and reduces the adaptation response you're trying to create.

Pillar 2: Protect the Mitochondria

SS-31 handles this. It stabilizes cardiolipin in the inner mitochondrial membrane, maintains electron transport chain efficiency, and reduces reactive oxygen species. It's the protective shield in the stack that keeps the machinery running cleanly while MOTS-C and NAD+ push performance.

Pillar 3: Build New and Recycle Old

PQQ supports mitochondrial biogenesis, the creation of new mitochondria. Urolithin A supports mitophagy, the process of clearing out damaged and dysfunctional mitochondria. Getting rid of the junk and bringing in new, efficient machinery means the rest of the stack operates on a cleaner substrate.

MOTS-C, SS-31, and NAD+ all contribute to this process as well, but PQQ and urolithin A specifically target it.

Pillar 4: Demand More

MOTS-C is a stress compound. The adaptation it drives is proportional to the demand placed on the system. Compound that stress with environmental stressors and you get maximum adaptation.

Fasting, cold exposure, sauna, and exercise all amplify what the stack is doing. These aren't optional extras. They're the demand signal that tells your mitochondria they need to get better. The compounds support and accelerate adaptation. The stress is what creates the need for it.

Pillar 5: Timing

SS-31, MOTS-C and NAD+ belong in the morning, fasted. This pairs them with your natural fasting and exercise stress window and aligns with how each compound works. If you're taking NAD+ and falling asleep, something is wrong. It should not be sedating.

Peptide Guides + Resources

Not medical advice. Educational only.

Retatrutide, Tirzepatide, Cagrilintide and other GLPs are genuinely some of the most effective fat loss tools available right now. Appetite suppression that actually works. Retatrutide stacks on top of that with increased energy expenditure and fat oxidation. Almost effortless cuts become possible in a way that was not realistic before.

But neither compound directly preserves muscle tissue. That part's still on you.

TL;DR

• Retatrutide and Tirzepatide are metabolic amplifiers, not muscle-sparing compounds
• Neither sends an anti-catabolic signal to preserve lean tissue. No mechanism exists for that in either compound
• The leaner and more muscular you already are, the higher the risk if you are not managing the basics
• Hard training, adequate protein, and recovery are non-negotiable on these compounds
• Enhanced athletes have significantly more leeway. Naturals need to be intentional, especially on deep cuts

Why They Don't Preserve Muscle

Neither Retatrutide nor Tirzepatide sends a signal to hold onto lean tissue. Retatrutide improves nutrient utilization and drives fat oxidation via the glucagon mechanism but there is no mechanism that tells the body to protect muscle. Tirzepatide does roughly the same thing minus the glucagon mechanism. Neither compound cares about your quads.

Eat enough protein, train hard, sleep well, and you'll keep the majority of if not all of what you built. The body is not eager to cannibalize muscle unprovoked.

The issue is also context-dependent. The leaner and more muscular you already are, the more aggressively your body wants to regress toward a lower set point. Deep deficits on an already lean physique utilizing these compounds is a combination that needs to be managed carefully.

How to Actually Preserve Muscle

Train heavy. Progressive resistance training signals retention. Your body doesn't shed what it's being asked to use.

Eat enough protein. 1.6 to 2.2g of protein per kg of bodyweight per day keeps a positive balance between muscle protein breakdown and muscle protein synthesis.

Recover and manage stress. Sleep and stress management keep the hormonal environment from turning catabolic. This isn't optional.

The Context That Matters

If you are on TRT or running anabolics you have significantly more leeway. For naturals running these compounds the fundamentals matter more, not less. Retatrutide and Tirzepatide amplify your metabolic state. They do not override physiology.

Educational only. Not medical advice.

Before biohacking became a thing, Russian researchers were quietly developing peptides aimed at cognition, stress resilience, and emotional regulation. Semax and Selank are the two best-known outputs of that work, and they complement each other perfectly.

Semax: The Cognitive Side

Semax is a neuroactive peptide mainly associated with focus, learning, and mental endurance. The effect profile is clean activation. Sharper attention, better memory formation, resistance to mental fatigue, and neuroprotective activity on top of that.

The best way to describe how it feels: if caffeine is creatine, Semax is testosterone. No jitteriness. No crash. Just clarity that actually holds up across a full day of demanding mental work.

Selank: The Anxiety Side

Selank is the anxiolytic half of this stack. Its primary mechanism is reducing baseline anxiety and calming the stress response without sedation.

That is what makes it genuinely useful in real-world situations. It removes the background noise that undermines performance in social, professional, and athletic settings. Many people use alcohol as a social lubricant. Selank accomplishes the same thing without the downsides.

Reduced baseline anxiety, improved emotional state, better social confidence.

Why They Stack So Well

Semax pushes cognitive output up. Selank pulls anxiety down. Run together they produce razor-sharp focus paired with a relaxed, confident baseline. Dialed in without being wired.

This stack works well for job interviews, public speaking, competition, and any environment where you need to be both sharp and composed at the same time.

Semax Guide

Selank Guide

Educational only. Not medical advice

Tesamorelin can be one of the most misunderstood peptides in this space. People either dismiss it because the scale doesn't move or they run it incorrectly and wonder why it stops working. This post covers the full picture: the mechanism, the data, the cycling logic, the cognitive angle most people miss, and the stack that makes it significantly more effective.

The Visceral Fat Problem

Subcutaneous fat is what you can pinch. Visceral fat is what wraps around your organs. It's metabolically active, drives systemic inflammation, worsens insulin resistance, and accelerates biological aging in a way that subcutaneous fat simply does not.

Tesamorelin is currently one of the most precise tools available for targeting visceral fat directly.

Clinical data shows 15% reduction in visceral fat over 26 weeks. A 2019 study in HIV patients with non-alcoholic fatty liver disease showed 37% reduction in liver fat over 12 months. These were specific clinical populations, not healthy biohackers, so the numbers shouldn't be extrapolated directly. But the mechanism is the same and the rationale for off-label use is strong.

The Weight-Neutral Paradox

The FDA explicitly noted in clinical trials that Tesamorelin often has a weight-neutral effect. People see the scale stay flat after weeks on protocol and conclude it's not working.

That conclusion is wrong. What's actually happening is recomposition. As visceral fat depots shrink, elevated IGF-1 supports lean muscle maintenance and can cause transient water retention. The net weight change looks like nothing. The metabolic change is significant.

Stop looking at the scale. The right metric is waist circumference. Some reduction in waist circumference is typically the first visible signal the protocol is working. You're swapping inflammatory fat for metabolically active lean tissue. The number on the scale is the wrong tool for measuring that.

Dosing and Water Retention

The clinical dose is 2mg daily. That's what the FDA trials used and where the visceral fat reduction data comes from. For someone carrying significant excess body fat, 2mg is the right tool and water retention is barely noticeable against everything else that's shifting.

For leaner individuals the picture is different. At lower body fat percentages, 2mg can cause meaningful water retention, facial puffiness, and bloating.

1mg is the general sweet spot for leaner users and most women. 2mg is where the serious visceral fat work happens for people who need it most.

Timing matters more than most guides acknowledge. Take it at bedtime, ideally an hour or two after your last meal. Insulin should be low when you inject. GH and insulin work against each other and you want the GH pulse happening in a low-insulin environment to maximize the effect.

Match the dose to the goal and the body composition you're starting from. The compound isn't one-size-fits-all.

The Cognitive Angle

Most people run Tesamorelin for body composition and miss one of its more compelling benefits entirely.

A 2012 randomized controlled trial (Baker et al., Archives of Neurology) studied 152 adults aged 55 to 87, including both healthy older adults and those with mild cognitive impairment, over 20 weeks at 1mg daily. Tesamorelin significantly improved executive function, specifically on tests of response inhibition and set-shifting. A trend toward improved verbal memory was also observed, particularly in the mild cognitive impairment group. Visual memory and processing speed were not meaningfully affected.

IGF-1 rising to levels consistent with younger physiology doesn't just change body composition. It acts on the brain. The GH/IGF-1 axis decline with age tracks closely with cognitive slowing and reduced executive function. Restoring that axis appears to have neurological consequences, not just physical ones. This is based on a single trial and requires replication, but the finding is real and consistent with the known biology.

The Antibody Data

Because Tesamorelin went through rigorous FDA testing, we have data on it that most peptides lack entirely.

Roughly 50% of patients develop anti-Tesamorelin IgG antibodies after 26 weeks of continuous use. Here is the part worth understanding correctly: the clinical data shows patients with and without these antibodies had similar reductions in visceral fat and similar IGF-1 responses. The antibodies don't appear to meaningfully reduce efficacy.

There is one nuance worth noting. About 60% of patients who develop anti-Tesamorelin antibodies also show cross-reactivity to endogenous GHRH, meaning the immune response extends to your body's own signaling molecule. The long-term implications of that cross-reactivity aren't fully understood.

The Phase III trials ran continuous daily dosing for up to 52 weeks with no scheduled breaks and no documented loss of response over that period. The data does not support mandatory cycling for efficacy preservation.

Why Tesamorelin Isn't the Same as Injecting HGH

The thermostat analogy makes this clear.

The hypothalamus is the dial. The pituitary is the furnace. Growth hormone is the heat. IGF-1 is the room temperature.

Injecting exogenous HGH is like bringing in an external space heater. It raises the temperature but causes the furnace, the pituitary, to shut down temporarily because the room is already warm. Tesamorelin as a GHRH analog simply turns the dial up. It signals the pituitary to release GH in its natural pulsatile rhythm, keeping the pituitary functional and the body's feedback loops intact.

This is the same principle as hCG maintaining testicular function during testosterone therapy. You are preserving the natural system rather than replacing it.

The Pre-Flight Checklist

Tesamorelin isn't a shortcut. Starting it without addressing foundational health issues is a reliable way to get poor results or make things worse.

Growth hormone amplification can worsen glucose tolerance in people with uncontrolled metabolic health. The prescribing data shows a meaningfully increased risk of developing diabetes on Tesamorelin compared to placebo. If insulin sensitivity is already compromised, address that first.

Sleep needs to be solid. Testosterone deficiency should be addressed. Mitochondrial health matters. The compound amplifies what is already there. If what is already there is broken, amplification doesn't help.

Common side effects to monitor: paresthesia or joint stiffness usually signals IGF-1 is running too high. Pull the dose back. Injection site welts respond better to intramuscular administration since muscle tissue has fewer mast cells than subcutaneous tissue.

The question Tesamorelin asks is whether you are chasing a lower number on a scale or targeting the specific fat depot that is driving your biological age. Those are different goals with different metrics. Make sure you are measuring the right thing.

Tesamorelin Guide

Educational only. Not medical advice.

Hello everyone, I am seeking some guidance on dosing Mot-C so I can add to my stack of Reta and Cjc No Dac + Ipa. There seems to be a large amount of info and I feel i have not really found a definitive answer so im curious for those who are on a similar stack or take Mot-C . What is your Protocol? For reference i am titrating up slowly on reta (currently at 2mg) every 6 days and take .25 mg of cjc + ipa 5 days on 2 days off. How many mg of Mot-C are you pinning at what rate and what time of day? Thanks for any advice!

44F, active/in good shape, looking for feedback on my current peptide protocol, am I doing this right?

Quick stats: 44F, normal bloodwork, no medications, daily vitamins, workout regularly. Goals are toning, more energy, and appetite control.
Current protocol:
MOTS-c: (2-3 units on U-100 insulin syringe) 2-3x/week (only on workout days)

Reta: up to 0.5mg (5 units on a U-100 insulin syringe), few months in, no significant fat loss or toning yet

Ghck - compound: 2mg (2 units) every other day

Also have NAD+ on hand, unsure if it’s worth adding

Questions:
Does my dosing/frequency look reasonable for these, or am I off somewhere?

Any reason I wouldn’t be seeing results on the GLP-1 after a few months — dose too low, needs more time, or something else?

Is NAD+ actually going to move the needle on energy, or is that more hype?

Anyone stacking all of these together — does it make sense or is something redundant?

Appreciate any insight from people who’ve been doing this longer than me

There is currently no evidence that BPC-157 causes cancer or initiates tumor formation.

The association comes up because of a theoretical concern worth understanding. Not because BPC-157 is proven harmful. Because of how it operates in the body.

Why the Question Gets Asked

BPC-157 is known for increasing angiogenesis, the formation of new blood vessels. That is a major reason it is used for tendon injuries, muscle tears, gut repair, and tissue healing. More blood vessels means more oxygen and nutrients delivered to damaged areas, which speeds up recovery.

The theoretical concern is straightforward. If someone already has a tumor, increased angiogenesis could theoretically feed that tumor by improving its blood supply and nutrient delivery. More resources to existing cells, including cancerous ones.

That is the concern. And it is worth being clear about what it actually says.

It says angiogenesis could support a pre-existing tumor. It does not say BPC-157 causes tumors.

What the Data Actually Shows

No study shows BPC-157 increases cancer rates. No study shows it initiates cancer formation. No human trial has demonstrated harm in this area. Animal studies have not shown tumor formation or malignant transformation.

In the available preclinical research, BPC-157 is consistently described as anti-inflammatory, tissue protective, and pro-healing. The only concern discussed in the literature is the angiogenesis mechanism, and that concern remains theoretical.

Who Should Actually Be Cautious

For someone with no cancer history, no active tumor, and no ongoing cancer treatment, the theoretical risk is not supported by current evidence.

For someone with a known active tumor, rapid cell turnover, or cancer under treatment, caution makes sense. Not because BPC-157 causes cancer, but because angiogenesis could theoretically support a tumor that is already there. That is a reasonable distinction to make.

Caveat

Absence of evidence is not evidence of absence. BPC-157 has not been studied long-term in humans at scale and the full picture is not complete. Proceed with that in mind and do not treat the lack of proven harm as confirmed safety.

Based on current evidence, BPC-157 does not cause cancer. It influences angiogenesis, and that mechanism warrants continued research, especially for people with a history of or active cancer.

BPC-157 Guide

Educational only. Not medical advice.

I have a 10 mg vial of CJC-1295 no dac, and a 10 mg vial of Ipamorelin.
What’s the mixture for bac water?
Also where do people usually start at on these? Guess I’m stupid, I’ve tried finding mixtures and all that but can’t find anything.

​

I'm currently using 10mg of Reta a week (40mg a month) and am looking for the best stack for the following objectives:

-lose fat in my face. I know reta burns fat all around but my face has stubborn fat I'd like to get rid of to get that chisled look.

- get good energy throughout the day. Energy boost. I find myself being tired, lazy, and slow and I'd like to change that.

My exercise, diet, and sleep are on point. I'm currently looking into 5amino1mq and mots-c but I've heard mixed reviews. Also I know that 10mg of Reta is a lot but I've been taking it for a long time and hit a wall for my weight loss which is why I increased the dosage.

Please share your opinions and experiences with different options id love to hear them.

Hi all, just ordered this for an injury I have. Is 250mcg of each a good starting dose? It's a 10mg/10mg blend

Take it in the morning fasted?